Literature DB >> 15604198

Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy.

Lars Bode1, Erik A Eklund, Simon Murch, Hudson H Freeze.   

Abstract

Protein-losing enteropathy (PLE), the excessive loss of plasma proteins through the intestine, often correlates with the episodic loss of heparan sulfate (HS) proteoglycans (HSPG) from the basolateral surface of intestinal epithelial cells. PLE onset is often associated with a proinflammatory state. We investigated whether loss of HS or treatment with the proinflammatory cytokine TNF-alpha directly causes protein leakage and whether a combination of both exacerbates this process. We established the first in vitro model of PLE and measured the flux of albumin/FITC through a monolayer of intestinal HT29 or Caco-2 cells grown on transwells and determined the integrity by transepithelial electrical resistance (TER). Loss of HS from the basolateral surface, either by heparanase digestion or by inhibition of HS synthesis, increased albumin flux 1.58 +/- 0.09-fold and reduced TER by 23.4 +/- 6.5%. TNF-alpha treatment increased albumin flux 4.04 +/- 0.03-fold and reduced TER by 75.7 +/- 4.7% but only slightly decreased HS content. The combined effects of HS loss and TNF-alpha treatment were not only additive, but synergistic, with a 7.00 +/- 0.11-fold increase in albumin flux and a 83.9 +/- 8.1% reduction of TER. Coincubation of TNF-alpha with soluble HS or heparin abolished these synergistic effects. Loss of basolateral HS directly causes protein leakage and amplifies the effects of the proinflammatory cytokine TNF-alpha. Our findings imply that loss of HSPGs renders patients more susceptible to PLE and offer a potential explanation for the favorable response some PLE patients have to heparin therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15604198     DOI: 10.1152/ajpgi.00461.2004

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  15 in total

Review 1.  Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.

Authors:  Sean Gill; Thomas N Wight; Charles W Frevert
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

2.  Glycoproteomics: protein modifications for versatile functions. Meeting on glycoproteomics.

Authors:  Reiko T Lee; Gordan Lauc; Yuan C Lee
Journal:  EMBO Rep       Date:  2005-11       Impact factor: 8.807

Review 3.  The endothelial glycocalyx: composition, functions, and visualization.

Authors:  Sietze Reitsma; Dick W Slaaf; Hans Vink; Marc A M J van Zandvoort; Mirjam G A oude Egbrink
Journal:  Pflugers Arch       Date:  2007-01-26       Impact factor: 3.657

Review 4.  Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection.

Authors:  Inkyung Kang; Mary Y Chang; Thomas N Wight; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

5.  Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.

Authors:  Kurt R Schumacher; Michael Cools; Bryan H Goldstein; Viktoriya Ioffe-Dahan; Karen King; Diane Gaffney; Mark W Russell
Journal:  Pediatr Cardiol       Date:  2011-06-10       Impact factor: 1.655

6.  Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.

Authors:  Martin Floer; Martin Götte; Martin K Wild; Jan Heidemann; Ezeddin Salem Gassar; Wolfram Domschke; Ludwig Kiesel; Andreas Luegering; Torsten Kucharzik
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

7.  The Fontan pathway: What's down the road?

Authors:  Sachin Khambadkone
Journal:  Ann Pediatr Cardiol       Date:  2008-07

Review 8.  Consensus guideline for the diagnosis and management of mannose phosphate isomerase-congenital disorder of glycosylation.

Authors:  Anna Čechová; Ruqaiah Altassan; Delphine Borgel; Arnaud Bruneel; Joana Correia; Muriel Girard; Annie Harroche; Beata Kiec-Wilk; Klaus Mohnike; Tiffany Pascreau; Łukasz Pawliński; Silvia Radenkovic; Sandrine Vuillaumier-Barrot; Luis Aldamiz-Echevarria; Maria Luz Couce; Esmeralda G Martins; Dulce Quelhas; Eva Morava; Pascale de Lonlay; Peter Witters; Tomáš Honzík
Journal:  J Inherit Metab Dis       Date:  2020-04-21       Impact factor: 4.982

9.  Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Authors:  Lars Bode; Camilla Salvestrini; Pyong Woo Park; Jin-Ping Li; Jeffrey D Esko; Yu Yamaguchi; Simon Murch; Hudson H Freeze
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 10.  Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.

Authors:  Esther Hermano; Immanuel Lerner; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.